共 19 条
- [1] STABLE GUT MICROBIOME COMPOSITION AND DIVERSITY WITH NGM282 THERAPY IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITISHEPATOLOGY, 2019, 70 : 1156A - 1157ASanyal, Arun J.Ling, LeiDinh, Duy M.Baxter, BryanDePaoli, AlexHarrison, Stephen A.Loomba, Rohit
- [2] TREATMENT WITH NGM282 SIGNIFICANTLY IMPROVES LIVER HISTOPATHOLOGY IN A MOUSE MODEL OF NON-ALCOHOLIC STEATOHEPATITIS (NASH)JOURNAL OF HEPATOLOGY, 2015, 62 : S694 - S694Luo, J.Ko, B.To, C.Ling, L.Rossi, S.DePaoli, A.Tian, H.
- [3] ALDAFERMIN (NGM282) IMPROVES APRI, FIB-4 AND OTHER NON-INVASIVE MEASURES IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITISHEPATOLOGY, 2020, 72 : 890A - 891AAbdelmalek, Manal F.Ling, LeiRyan, Marno C.Roberts, Stuart K.Trotter, James F.Paredes, AngeloNeff, GuyYan, Andrew Z.DePaoli, AlexLieu, HsiaoHarrison, Stephen A.
- [4] Aldafermin (NGM282) reduces the cross-linked pro-peptides of type III collagen PRO-C3X, a novel biomarker, in non-alcoholic steatohepatitis and primary sclerosing cholangitis patientsJOURNAL OF HEPATOLOGY, 2020, 73 : S526 - S526Harrison, StephenLing, LeiTrotter, James F.Paredes, AngeloYan, AndrewBeuers, UlrichHirschfield, GideonLeeming, DianaKarsdal, MortenDePaoli, AlexLieu, Hsiao
- [5] Changes in Serum Bile Acids Correlate with 7alpha-Hydroxy-4-Cholesten-One and Fibrogenesis Biomarker Pro-C3 with NGM282 Therapy in Patients with Non-alcoholic SteatohepatitisJOURNAL OF HEPATOLOGY, 2019, 70 (01) : E156 - E156Sanyal, ArunLing, LeiJaros, MarkBaxter, BryanKowdley, Kris V.DePaoli, AlexHarrison, Stephen
- [6] BILE ACIDS AND LIVER FIBROSIS: SHARED ANTI-FIBROTIC EFFECTS OF NGM282, AN FGF19 ANALOGUE, IN PRIMARY SCLEROSING CHOLANGITIS AND NON-ALCOHOLIC STEATOHEPATITISHEPATOLOGY, 2019, 70 : 806A - 807AHirschfield, GideonLing, LeiJaros, MarkSanyal, Arun J.Kowdley, Kris V.Mayo, Marlyn J.Beuers, UlrichDePaoli, AlexHarrison, Stephen A.
- [7] NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trialLANCET, 2018, 391 (10126): : 1174 - 1185Harrison, Stephen A.Rinella, Mary E.Abdelmalek, Manal F.Trotter, James F.Paredes, Angelo H.Arnold, Hays L.Kugelmas, MarceloBashir, Mustafa R.Jaros, Mark J.Ling, LeiRossi, Stephen J.DePaoli, Alex M.Loomba, Rohit
- [8] NGM282, AN FGF19 ANALOGUE, REDUCES NET DEPOSITION OF COLLAGEN III IN NON-ALCOHOLIC STEATOHEPATITIS AND PRIMARY SCLEROSING CHOLANGITISHEPATOLOGY, 2019, 70 : 1240A - 1241AHarrison, Stephen A.Ling, LeiNielsen, Mette JuulTrotter, James F.Paredes, Angelo H.Yan, Andrew Z.Beuers, UlrichHirschfield, GideonLeeming, Diana J.Karsdal, MortenDePaoli, Alex
- [9] Positive topline results from a 24-week, randomized, doubleblind, placebo-controlled, multicenter, phase 2 study of the FGF19 analogue aldafermin (NGM282) in patients with non-alcoholic steatohepatitisJOURNAL OF HEPATOLOGY, 2020, 73 : S114 - S115Harrison, Stephen A.Neff, GuyGuy, CynthiaBashir, MustafaParedes, AngeloFrias, JuanYounes, Ziad H.Trotter, James F.Gunn, Nadege T.Moussa, SamKohli, AnitaNelson, KristenGottwald, MildredChang, WilliamYan, AndrewDepaoli, AlexLing, LeiLieu, Hsiao
- [10] NGM282 EXHIBITS POTENT ANTI-INFLAMMATORY AND ANTI-FIBROTIC ACTIVITY IN FXR-NULL MICE WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) HISTOPATHOLOGYJOURNAL OF HEPATOLOGY, 2015, 62 : S694 - S695Ling, L.Zhou, M.Yang, H.Humphrey, M.Learned, M.Rossi, S.DePaoli, A.Tian, H.